Log in

Auris Medical Stock Forecast, Price & News

-0.02 (-2.47 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $0.79
50-Day Range
MA: $0.84
52-Week Range
Now: $0.79
Volume90,066 shs
Average Volume794,031 shs
Market Capitalization$5.60 million
P/E RatioN/A
Dividend YieldN/A
Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.
Read More
Auris Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EARS



Sales & Book Value

Annual SalesN/A
Book Value$1.47 per share



Market Cap$5.60 million
Next Earnings DateN/A
OptionableNot Optionable
-0.02 (-2.47 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Auris Medical (NASDAQ:EARS) Frequently Asked Questions

How has Auris Medical's stock price been impacted by Coronavirus?

Auris Medical's stock was trading at $0.8829 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EARS shares have decreased by 10.5% and is now trading at $0.7901.
View which stocks have been most impacted by COVID-19

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd. (NASDAQ:EARS) released its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60.
View Auris Medical's earnings history

When did Auris Medical's stock split? How did Auris Medical's stock split work?

Auris Medical's stock reverse split before market open on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

Who are some of Auris Medical's key competitors?

What other stocks do shareholders of Auris Medical own?

Who are Auris Medical's key executives?

Auris Medical's management team includes the following people:
  • Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 52)
  • Mr. Elmar Schaerli CPA, Chief Financial Officer (Age 48)

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $0.79.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $5.60 million. The biotechnology company earns $-6,680,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Auris Medical employs 8 workers across the globe.

What is Auris Medical's official website?

The official website for Auris Medical is www.aurismedical.com.

How can I contact Auris Medical?

Auris Medical's mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The biotechnology company can be reached via phone at 441-295-5950 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.